Company intelligence / Profile preview

Gertrude Biomedical

Melbourne / Parkville, Victoria, Australiagertrudebiomed.com ↗

Ownership: Private
Employees: ~30
Development stage: Preclinical

Overview

Gertrude Biomedical is developing innovative small molecule inhibitors targeting the SOX18 transcription factor for the treatment of cancers and diseases characterized by abnormal blood vessel growth. Their lead program is in preclinical development. No clinical results have been reported as of May 2025.

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Partnerships

Springboard Enterprises

Beyond the preview

Go deeper on Gertrude Biomedical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gertrude Biomedical.

Explore the full profile